SEARCH

SEARCH BY CITATION

References

  • 1
    Van Deventer SJ. Immunotherapy of Crohn's disease. Scand J Immunol 2000; 51: 1822.
  • 2
    Hommes DW, Van Deventer SJ. Anti- and proinflammatory cytokines in the pathogenesis of tissue damage in Crohn's disease. Curr Opin Clin Nutr Metab Care 2000; 3: 1915.
  • 3
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337(15): 102935.
  • 4
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 5
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 7619.
  • 6
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 15419.
  • 7
    Sands B, Van Deventer S, Bernstein C, et al. Long-term treatment of fistulizing Crohn's disease: response to infliximab in the Accent II trial through 54 weeks. Gastroenterology 2002; 122: A81(Abstract).
  • 8
    Centocor. Remicade Safety Experience. Clinical Trial and Post Marketing Data. PSUR7. Malvern, PA: Centocor, 2003: data on file.
  • 9
    Brzezinski A, Armstrong L, Alvarez Del Real G, et al. Infliximab does not increase the risk of complications in the peri-operative period in patients with Crohn's disease. Gastroenterology 2002; 122(4): W1363.
  • 10
    Colombel JF, Loftus EV, Tremaine WJ, et al. Perioperative infliximab and/or immunomodulator therapy is not associated with increased postoperative complications in Crohn's disease. Gastroenterology 2002; 124: A521(Abstract).
  • 11
    Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 3207.